Andere talen Exagen Inc.

Aandelen

XGN

US30068X1037

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,41 ^USD	+2,17%		-1,32%	-29,15%

18/03	Exagen Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
18/03	Transcript : Exagen Inc., Q4 2023 Earnings Call, Mar 18, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M	18/03
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18/03
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18/03
Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	18/03
Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
North American Morning Briefing : Investors -2-	18/03
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08/03
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08/03
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024	07/03
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference	30/01
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07/01
Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023	07/01
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07/01
Exagen Files $150 Million Mixed Shelf	20/11
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $13.4M, vs. Street Est of $10.3M	13/11
Exagen Inc. Reports Strong Third Quarter 2023 Results	13/11
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers	09/11
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	02/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Exagen Inc.

Aandelen

XGN

US30068X1037

Andere talen

Filters